Altogether, our results confirm that PI3K/Akt and ERK1/2 are pro-survival kinase pathways triggered by LPS/TLR4, suggesting TLR4 activation as a potential pharmacological target to confer CF protection in the I/R context. The gene discussed is AKT1; the disease is cystic fibrosis.